Title: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Authors: Druker, Brian J ×
Guilhot, François
O'Brien, Stephen G
Gathmann, Insa
Kantarjian, Hagop
Gattermann, Norbert
Deininger, Michael W N
Silver, Richard T
Goldman, John M
Stone, Richard M
Cervantes, Francisco
Hochhaus, Andreas
Powell, Bayard L
Gabrilove, Janice L
Rousselot, Philippe
Reiffers, Josy
Cornelissen, Jan J
Hughes, Timothy
Agis, Hermine
Fischer, Thomas
Verhoef, Gregor
Shepherd, John
Saglio, Giuseppe
Gratwohl, Alois
Nielsen, Johan L
Radich, Jerald P
Simonsson, Bengt
Taylor, Kerry
Baccarani, Michele
So, Charlene
Letvak, Laurie
Larson, Richard A #
Issue Date: Dec-2006
Series Title: The New England Journal of Medicine vol:355 issue:23 pages:2408-17
Abstract: BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. RESULTS: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P<0.001). Grade 3 or 4 adverse events diminished over time, and there was no clinically significant change in the profile of adverse events. CONCLUSIONS: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. ( number, NCT00006343 [].)
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Hematology Section (-)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science